Drug Trial Radar · NCT00899379
Treatment of Multiple Attacks of Acute Migraine (0462-025)
Last checked: Nov 19, 2026Latest source record: Feb 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
473
Actual
Start
Apr 1995
Primary completion
Jan 1996
Study completion Apr 1996
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- May 12, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study to evaluate rizatriptan for the treatment of multiple attacks of acute migraine compared to placebo.
Conditions
- Migraine Headache
Interventions
rizatriptan benzoateDrug
Rizatriptan 10 mg p.o. at onset of moderate to severe migraine headache
Comparator: PlaceboDrug
Placebo to Rizatriptan, Oral Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pain Relief at 2 Hours During the First Migraine Attack PeriodTime frame: 2 hours
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.